One third of men with lymph node-positive penile cancer don't receive a lymph node dissection, the recommended care associated with an overall survival advantage, researchers from Fox Chase Cancer Center have found. The paper appears in JAMA Oncology.
The New England Journal of Medicine Feb. 22 published data for larotrectinib in the treatment of pediatric and adult patients whose tumors harbor tropomyosin receptor kinase gene fusions. Loxo Oncology Inc. and Bayer AG are developing the agent
Guidelines developed collaboratively by the American Society of Clinical Oncology and the National Comprehensive Cancer Network offer clinicians recommendations for assessment and management of side effects related to immune checkpoint inhibitors.
Analysis of the phase II CONDOR trial indicates that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic head and neck cancer and has the potential to slow growth in tumors with low or negative expression of the PD-L1 protein.
A new study from the University of Wisconsin Carbone Cancer Center highlights a disparity in cancer care: the depressed spouses of cancer patients are 33 percent less likely to receive adequate treatment for depression than are patients whose spouses don't have cancer. Couples who live in rural areas are 72 percent less likely to receive recommended care for depression (including medication and talk therapy) than the depressed spouses of those without cancer.
Genentech announced results from the positive phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
Bristol-Myers Squibb Company said the ongoing phase III CheckMate-227 study met its co-primary endpoint of progression-free survival with the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination versus chemotherapy in first-line advanced non-small cell lung cancer patients whose tumors have high (≥10 mutations/megabase, mut/mb) tumor mutation burden, regardless of PD-L1 expression.
Tyme Technologies Inc. announced efficacy and safety data from an ongoing phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer.
Novartis has announced updated results from the pivotal ELIANA clinical trial of Kymriah (tisagenlecleucel), formerly CTL019, in relapsed or refractory (pediatric and young adult patients with B-cell acute lymphoblastic leukemia have been published in The New England Journal of Medicine. New data include longer-term follow-up and efficacy in 75 infused patients, analysis of expansion and persistence of Kymriah, and longer-term safety.
Bristol-Myers Squibb Co. announced new data from a cohort of the phase II CheckMate -142 trial evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with DNA mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer.
